Division of Urology — Research

Research Opportunities

The program is supplemented by the opportunity for scholarly activities and research. Residents are encouraged to plan projects and to arrange collaborations with other disciplines in the UTMB area. Current projects in the various urology laboratories of the program include research work in population-based outcomes in urologic oncology and in particular prostate and bladder cancer. This is balanced with opportunities to engage in basic science research in tumor immunology, molecular biology and oncogenes, novel combination chemotherapeutic approaches, tumor metastases, and infectious related diseases. This experience affords the resident an opportunity to write scientific papers and to present data at national and international meetings.

Urology facultyRich Environment of Active Research

Recognition of the need for a personalized approach to medicine has long been a focus of the Department of Surgery and Division of Urology initiatives. The impact of treatment-related morbidity and the burden of urologic diseases on national healthcare expenditures mandate improved ability to select patients for appropriate treatments and to predict outcomes. Evaluation of healthcare outcomes and comparative treatment efficacies is a key component of our healthcare outcomes, policy initiatives and an intense area of research focus for the division.

Health Services Research

Faculty within the Division of Urology actively engage in multi-disciplinary investigation to improve the quality and value of health care delivered to patients with benign and malignant urologic disease. Faculty within the Division continue to lead landmark studies characterizing the downstream effects of bladder cancer and its treatment. Furthermore, ongoing research within the Division seeks to bridge the gap between health services research and quality improvement to optimize care delivered to patients at UTMB and across the United States.

Recent Publications

Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer in JAMASurgery, 2018

Radical Cystectomy Survival Calculator (RCSC)

Radical Cystectomy Survival Calculator (RCSC) Article in Urology, 2017
Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making


Related Faculty and Staff

Stephen B. Williams, MD, MS, FACS
Chief, Division of Urology
Professor, Urology and Radiology (Tenured)
Robert Earl Cone Professorship
Director of Urologic Oncology
Director of Urologic Research
Co-Director Department of Surgery Clinical Outcomes Research Program
Medical Director for High Value Care, UTMB Health System 
Medical School: The George Washington University, Washington, DC
Internship: Harvard Program in Surgery, Brigham and Women's Hospital, Boston, MA
Residency: Harvard Program in Urology, Brigham and Women's Hospital, Boston, MA
Fellowship: Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Stephen B. Williams, MD, MS is Director of Urologic Research, and he is also Co-Director of the Department of Surgery Clinical Outcomes Research Program. Dr. Williams has expertise in health services research. His seminal research in comparative effectiveness regarding prostate cancer treatments has fueled his more recent interest in regards to discerning bladder cancer treatment patterns and optimizing outcomes. His research has been presented at the National Academies of Sciences, Engineering, and Medicine (previously known as the Institute of Medicine). He was named the Comparative Effectiveness in Research on Cancer in Texas (CERCIT) Scholar and his work will help pave the way for further understanding and optimizing the care we deliver to these patients.

yongYong Shan, PhD
Analyst II, Department of Surgery 
PhD: Forestry, University of Georgia, 2010
MS: Statistics, University of Georgia, 2009
MS: Forest Management, Chinese Academy of Forestry, 2006

Yong Shan, PhD has extensive experience in advanced statistical methodology including health services research applications concerning outcomes and costs. Dr. Shan's research projects include working with Dr. Williams to compare costs of Radical Cystectomy with Trimodal Therapy for patients diagnosed with localized muscle-invasive bladder cancer; population-based outcomes comparing Radical Cystectomy With Trimodal Therapy for patients diagnosed with localized muscle-invasive bladder cancer; and radical cystectomy and improved survival outcomes and decreased costs compared with trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer. Dr. Shan also works with Dr. Mehta to develop Comorbidity Score for Patients Undergoing Major Surgery.

ballargeonJacques G. Baillargeon, PhD
Associate Professor, Department of Preventive Medicine and Community Health
Director Community Health Services Division of Epidemiology
B.A.: University of Texas, Austin, English
Ph.D.: University of Texas Medical Branch, Galveston, Epidemiology
Post Doc Fellowship: University of Texas Medical Branch, Galveston, Clinical Epidemiology

After joining the faculty of the Department of Pediatrics at the University of Texas Health Science Center at San Antonio, Dr. Baillargeon returned to UTMB in September of 2006. His research interests include correctional health care, HIV, psychiatric epidemiology, cancer epidemiology, and epidemiologic methods. He is also the recipient of numerous research grants, including awards from the National Institutes of Health and the National Institute of Justice.

kuoYong-Fang Kuo, PhD
Professor, Department of Preventive Medicine and Community Health and Department of Internal Medicine
Director, Office of Biostatistics and Office of Biostatistics at the Sealy Center on Aging
BS: Taipei Medical College, Taipei, Taiwan (Nursing) 1984
MEd: National Taiwan Normal University, Taipei, Taiwan (Health Education) 1986
MAS: The Ohio State University, Columbus, OH (Applied Statistics) 1994
PhD: The Ohio State University, Columbus, OH (Biostatistics) 1997

Yong-Fang Kuo, PhD is the Director of Biostatistics at the Sealy Center on Aging and Professor in the Department of Internal Medicine. Dr. Kuo has more than 14 years' experience analyzing health administrative data. Through collaboration with multiple clinicians, she has more than 40 publications based on large administrative data and about 30 of them focused on cancer care. Dr. Kuo has extensive experience in the use of hierarchical generalized linear models (HGLM) to evaluate provider-specific variation in receipt of care. One example of her use of this methodology was to determine use of androgen-deprivation therapy for prostate cancer at the level of the urologist and patient.